drugset

drugset / Trial / NCT00849290

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

NCT00849290 ↗

Phase 2 Completed 113 enrolled Dendreon

NaSingle-groupOpen-labelTreatment

Summary

This is an open label, Phase 2 trial of APC8015F immunotherapy in men with objective disease progression on protocol D9902 part B (NCT00065442)

Timeline

Start: 2004-04
Primary completion: 2009-01
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	APC8015F	Cell therapy	—	—

Indications